RxDoctor Payments Data

Swarna Manian, MD

Internal Medicine · Virginia Beach, VANPI 1467426627

Payments from drug & device makers

$839in general payments, 2019–2025

Across 50 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$123
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$122
  • Novartis$96
  • Pfizer$95
  • AstraZeneca$74
  • Sanofi Pasteur Inc.$59
  • plus $269 from 8 others

What the payments were for

  • Food & beverage$839100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$839 in reported general payments places this provider in the 75th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$80,075
Medicare patients
279
Services billed
841

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$58,665
JardianceEmpagliflozin49$43,805
EliquisApixaban36$40,993
XareltoRivaroxaban15$12,999
Praluent PenAlirocumab13$6,367
DilantinPhenytoin Sodium Extended25$3,298
SynthroidLevothyroxine Sodium54$3,062
Rosuvastatin Calcium200$3,042
Atorvastatin Calcium163$1,965
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$1,962
Gabapentin118$1,962
Omeprazole121$1,785
Losartan Potassium149$1,550
Potassium Chloride16$1,137
Duloxetine Hcl38$1,045

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$49$58,66539 claims
PfizerEliquis, Dilantin$95$44,29161 claims
Boehringer IngelheimJardiance$28$43,80549 claims
AbbVieSynthroid$123$3,06254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →